The fact that Delta-8 THC is intoxicating and is not naturally occurring could cause the FDA to take a stricter approach with Delta-8 compared to its treatment of CBD.
This article originally appeared on Green Light Law Group and has been reposted with permission.
On May 4, 2022, the Food and Drug Administration (FDA) sent out warning letters to five companies distributing Delta-8 THC (FDA Warning Letters). This is the first time that the FDA specifically addressed products containing hemp-derived Delta-8.
In all but one of the letters, the FDA also warned about distributing products containing cannabidiol (CBD). Both Delta-8 and CBD can be derived from hemp. Hemp is a federally legal form of cannabis which has created a huge, quasi legal, market for these products. Up until this point, the FDA’s focus, when it comes to cannabis, has been on CBD. Now it appears that the FDA is also targeting Delta-8.
Each of the five FDA Warning Letters alleged the following violations: Distribution of new unapproved drugs containing Delta-8Distribution of misbranded drugs containing Delta-8Distribution of adulterated food containing Delta-8Delta-8 Drugs The FDA has not approved any drug containing Delta-8. The FDA Warning letters indicate that the five recipients are distributing unapproved drugs containing Delta-8. The FDA regulates a wide variety of products and has a system to classify those products under the Food, Drug and Cosmetics Act (FDCA). To determine whether a product is a drug, the FDA looks to how the product is marketed to establish its intended use. If medical, health or wellness claims are made about a product, regardless of what the product contains, then the product becomes a drug in the eyes of the FDA.
Here are some of the drug claims referenced in the FDA Warning Letters: Facebook post stating “Delta-8 THC is showing a lot of promise as an antiemetic that can relieve nausea and vomiting in pediatric cancer patients undergoing chemotherapy.”Instagram post stating “Preventing Vomiting . . . a small study suggested that Delta 8 THC is an effective option to treat vomiting during chemotherapy . . . Removes Anxiety”A webpage titled “What is Delta 8 THC?” containing the following: “In non-medical terms, researchers linked Delta 8-THC to anti-nausea (antiemetic), anti-anxiety (anxiolytic), and pain relief (analgesic) benefits, among other effects . . . It could also protect brain cells thanks to its neuroprotective effects.”A blog post titled, “Let’s [sic] Us Introduce You to Delta-8 THC” containing the following: “Delta-8 THC flower is an ideal option for medical users of cannabis who want to enjoy the benefits of THC without the sedative effects.”A product webpage stating “Delta-8 consumers report many of the same effects as THC . . . and relief from some symptoms such as pain . . . Delta-8 can also help with insomnia.” These examples were selected to illustrate that the FDA will look beyond a product’s labeling and packaging to determine whether or not it is a drug. The FDA reviews social media and websites to make its determination. In addition, claims do not need be explicit for the FDA to determine something is a drug. An outright claim that Delta-8 can cure or treat a disease constitutes a drug claim but even citing to a study on Delta-8 will put a target on your back.
In the FDA Warning Letters, the FDA also alleges that the Delta-8 drugs are misbranded because they fail to bear adequate directions for use. At this point, the FDA Warning Letters state that adequate instruction cannot be written because there are not adequate studies on Delta-8. The lack of studies also prohibits manufacturers of Delta-8 from determining safe dosing, up to the FDCA standard.
Getting a new drug approved by the FDA is incredibly expensive and therefore cost-prohibitive for most businesses. The FDA sets rigorous testing standards to establish a drug’s safety. There does not appear to be a clear path forward for the FDA to approve Delta-8 as a drug. Delta-8 in Food Both drugs and food are subject to the FDA’s premarket approval, but the standards are not the same. the FDA does require that food additives for use in any human or animal foods are generally regarded as safe (GRAS). The FDA has not concluded that Delta-8 is GRAS, meaning that it cannot be added to food. Unlike the allegations that Delta-8 products are unapproved and misbranded drugs, the FDA’s conclusion that the presence of Delta-8 adulterates food is based on the product’s ingredients not how it is marketed. Comparing CBD and Delta-8 in the FDA Warning Letters In the FDA Warning Letters, the FDA alleges that four of the five recipients (one only distributing Delta-8 products) of distributing unapproved drugs, misbranded drugs, and adulterated food containing CBD. Like Delta-8 a product containing CBD will be considered a drug based on how its marketed and if the product is food, the FDA will consider it adulterated because CBD is not GRAS (that is, “Generally Regarded as Safe” for human consumption).
Unlike Delta-8, CBD has been approved as a drug, in the form of Epidiolex, which invokes the “Drug Exclusion Rule.” The basic concept of the Drug Exclusion Rule is that once a substance is investigated as a drug, it cannot then be added to food or dietary supplements unless it was first marketed as a food or dietary supplement prior to the drug investigation. The FDA has concluded that the Drug Exclusion Rule applies to CBD because it has determined CBD was not marketed as a food or drug prior to the investigations that lead to Epidiolex.
The fact that the Drug Exclusion Rule does not apply to Delta-8 (or other cannabinoids that have not been investigated as drugs) means that it is possible that Delta-8 could be considered a new dietary ingredient (NDI) that could potentially be added to dietary supplements. Unlike food and drugs, dietary supplements do not require pre-market approval. Distributors of dietary supplements can make limited health and wellness claims (e.g., calcium is good for bone development). However, manufacturers of dietary supplements containing Delta-8 would need notify the FDA of the NDI including information that serves as the basis for the conclusion for any claims made about the product.